Abstract
Genomics and Proteomics Research in Europe is Thriving
The European Union (EU) has become a popular hub for advanced research into genomics and
proteomics. This can be attributed to the significant government funding at both the national level
and from individual EU agencies. Moreover, Europe houses some of the largest pharmaceutical
companies that are extending their support to research programs related to genomics and proteomics,
either in-house or in collaboration with smaller firms. The primary goal is to go beyond the realms
of human genome sequencing and expand the list of identified proteins and genes, which will
ultimately aid in understanding disease mechanisms and developing corresponding therapeutics.
This Technical Insights research service analyses key developments in proteomics and genomics and
its impact on the field of drug discovery and development. In addition to evaluating research trends
in companies and universities in the EU, this study evaluates the important technology drivers and
challenges. Participants can use this research service to identify potential collaborators, stay
ahead of the competition and remain abreast of critical developments.
Genomics and Proteomics Gaining Prominence as Primary Tools for Drug Discovery
While the potential of genomics and proteomics is constantly growing, the most lucrative
applications lie in the field of drug discovery and development and molecular diagnostics.
Proteomics and genomics are expected to be key tools in target identification and validation and
ultimately expanding the list of cellular targets. "New information on the molecular mechanisms
responsible for disease has enhanced the identification and validation processes," says the
analyst of this research. "With regard to molecular diagnostics, the expectation is that
diseases with a genetic component can be treated according to specific genetic markers, medications
and dosages that are optimized for individual patients."
Human genomic research is accelerating as scientists seek effective therapies with the ability to
target the appropriate genes for activation inhibition or replacement. The target genes are
multiplying in numbers and researchers are hoping to develop treatments for a wide variety of
disorders, from cystic fibrosis to cancer and cardiovascular disease.
Enabling Technologies are Accelerating Progress in Genomics and Proteomics
Emerging technologies such as microarrays, automation and robotics are taking genomics and
proteomics research to new heights. "Weeks, if not months, were initially required to elucidate
the expression of a single gene," observes the analyst. "Now, tens and thousands of genes
can be studied in a single afternoon." In addition, previously time-consuming and
skill-intensive assays and preparations can now be accomplished thousands of samples at a time and
within a few hours. This is made possible through new computer-modelling approaches such as
molecular dynamics (MD), ligand docking (LD), pharmacophore modelling (PM), homology modelling (HM)
and enzyme-substrate modelling (ESM).
Since conventional technologies such as 2D gel electrophoresis pose certain limitations,
development of new technologies such as isotope coded affinity tags, 2D chromatographic separation,
terahertz pulsed imaging (TPI) and terahertz pulsed spectroscopy (TPS) and protein arrays are also
gaining importance.
View Cart
